Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS: As compared with MPT, continuous lenalidomide- dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
|
Authors | Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell J White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin-Haynes, Hervé Avet-Loiseau, Cyrille Hulin, Thierry Facon, FIRST Trial Team |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 371
Issue 10
Pg. 906-17
(Sep 04 2014)
ISSN: 1533-4406 [Electronic] United States |
PMID | 25184863
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Thalidomide
- Dexamethasone
- Lenalidomide
- Melphalan
- Prednisone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Dexamethasone
(administration & dosage, adverse effects)
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Lenalidomide
- Male
- Melphalan
(administration & dosage)
- Middle Aged
- Multiple Myeloma
(drug therapy, immunology)
- Prednisone
(administration & dosage)
- Thalidomide
(administration & dosage, adverse effects, analogs & derivatives)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|